<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702117</url>
  </required_header>
  <id_info>
    <org_study_id>AJUAR</org_study_id>
    <secondary_id>EudraCT number:2007-006334-33</secondary_id>
    <nct_id>NCT00702117</nct_id>
  </id_info>
  <brief_title>Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias</brief_title>
  <acronym>AJUAR</acronym>
  <official_title>Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates 3 different populations:

      It is an open, randomized, parallel-group study comparing the effectiveness of intravenous
      (iv) ajmaline with currently used antiarrhythmic drugs in the acute treatment of :

        1. recent-onset atrial fibrillation versus iv flecainide

        2. sustained monomorphous ventricular tachycardia versus iv procainamide

      The study also evaluates in an open, randomized, crossover study, the use of iv ajmaline
      versus iv flecainide in the diagnosis of Brugada syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with reversion of atrial fibrillation</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with reversion of ventricular tachycardia</measure>
    <time_frame>15 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects developing EKG pattern diagnostic of Brugada Sd. after provocation test.</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Brugada Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV flecainide in atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ajmaline in atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iv procainamide in ventricular tachycardia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iv ajmaline in ventricular tachycardia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iv flecainide in diagnosis of Brugada Sd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>f</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iv ajmaline in diagnosis of Brugada Sd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flecainide</intervention_name>
    <description>2 mg/kg iv in 10 minutes</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>e</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ajmaline</intervention_name>
    <description>1 mg/kg iv in 10 minutes</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>d</arm_group_label>
    <arm_group_label>f</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procainamide</intervention_name>
    <description>10 mg/kg iv in 10 minutes</description>
    <arm_group_label>c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AF: Patients with isolated, idiopathic, sustained, symptomatic, recent onset(&gt;10
             minutes to &lt;24 hours) atrial fibrillation.

          -  VT: Patients with ventricular tachycardia with good haemodynamic tolerability
             attending the emergency room or induced at the electrophysiology lab during testing
             for ventricular arrhythmias.

          -  Brugada Sd (BrS): First-degree relatives of a patient with Brugada Syndrome with a ECG
             non-diagnostic of the BrS.

        Exclusion Criteria:

          -  General: Pregnancy

          -  AF: Pre-existing heart disease.

          -  Secondary AF

          -  2nd and 3rd degree AV block or RBBB associated with LAFB or LPFB (bifascicular block).

          -  LVF&lt;40%.

          -  Moderate-severe liver failure.

          -  AF with haemodynamic compromise.

          -  VT:VT with haemodynamic compromise.

          -  BrS:Pre-existing heart disease.

          -  2nd and 3rd degree AV block or RBBB associated with LAFB or LPFB (bifascicular block).

          -  Moderate-severe liver failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia</city>
        <state>Guipuzcoa</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Cardiología, Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>December 14, 2010</last_update_submitted>
  <last_update_submitted_qc>December 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>José Brugada</name_title>
    <organization>Hospital Clinic de Barcelona</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Ajmaline</mesh_term>
    <mesh_term>Lorajmine</mesh_term>
    <mesh_term>Procainamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

